drugset / Trial / NCT00835081
Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study is to compare the relative bioavailability of cefadroxil 500 mg capsules (manufactured by Teva Pharmaceuticals USA) with that of DURICEF® 500 mg capsules (manufactured by Bristol-Myers Squibb Company) when dosed (1 x 500 mg capsules) in normal healthy non-smoking male and female subjects under fed conditions.
Timeline
- Start
- 2004-09
- Primary completion
- 2004-10
- Completion
- 2004-10
Outcome
Met primary endpoint
registry Ratio of the T/R geometric mean x 100 103 (90% CI 95.9 to 110) NCT00835081 ↗
registry Ratio of the T/R geometric mean x 100 100 (90% CI 97.5 to 103) NCT00835081 ↗
registry Ratio of the T/R geometric mean x 100 99.8 (90% CI 97.4 to 102) NCT00835081 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cefadroxil | Small molecule | 500 mg | — |
Indications
No indication recorded.